Compare and evaluate two combination regimens of vinorelbine plus gemcitabine and cisplatin pins vinorelbine for treatment of patients with advanced non-small-cell lung cancer
- VernacularTitle:GN方案与NP方案一线治疗晚期非小细胞肺癌56例
- Author:
Delin WANG
;
Ruixuan FENG
;
Xueli MO
;
Yujuan CAO
;
Fang DU
;
Peng ZHAO
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small cell lung;
Antineoplastic combined chemotherapy
- From:
Cancer Research and Clinic
2008;20(7):476-478
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare and evaluate the clinical efficacy and side effect of vinorelbine plus gemcitabine and vinorelbine plus cisplatin combinations in advanced non-small-cell lung cancer(NSCLC). Methods 56 cases with non-treated advanced NSCLC were unrandomly divided into two groups: the GN group (27patients) treated with vinorelbine plus gemcitabine, the NP group (29 patients) treated with vinorelbine plus cisplatin,1/3 weeks×2～6 cycles. Results For the GN group, the overall response rate was 37.7 %, MTTP was 5.1months,one year survival rate (1-ySR) was 40.7 %. There were no significant difference in the response rates and the survival rates for the GN group compared with the NP group (P ＞0.05); But on the side effect of toxicities, WHO grade anemia and nausea/vomiting and tiredness of the GN group was significantly milder than the NP group (P ＜ 0.05). Conclusion Vinorelbine combined Gemcitabine regimen (GN) is active and well-tolerated. It is worth to investigate GN recommended as the first line chemotherapeutic regimen for the treatment of patients with advanced NSCLC.
